Differences in disease characteristics and outcomes as determined by biological sex in a large UK IPF population: Analysis from the British Thoracic Society, Interstitial Lung Disease (BTS-ILD) registry data

Competing Interest Statement

SB has received speaker honoraria from Boehringer Ingelheim and Astra Zeneca, outside the submitted work. SM has received speaker honoraria from Boehringer Ingelheim, outside the submitted work. GD is a member of the BTS ILD registry steering committee, outside the submitted work.

Funding Statement

SM has received funding through NHSE-NIHR predoctoral award to undertake this project. The British Thoracic Society wholly funds the UK Interstitial Lung Disease Registry. The Healthcare Quality Improvement Partnership (HQIP) provided a starter grant (2011 to 2013). Boehringer Ingelheim and InterMune each provided a grant to support the development of additional electronic features in 2014.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The UK ILD (Interstitial lung disease) registry has ethical approval (National Research Ethics Service (NRES) reference 12/EE/0381 and renewal 12/EE/0346).This publication makes use of data purchased from the British Thoracic Society Interstitial Lung Disease Registry Programme, which has no responsibility or liability for the accuracy, currency or correctness of this publication. The project was peer reviewed by the BTS prior to release of the data.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes